Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
07 11월 2023 - 4:00AM
Information on the Total Number of Voting Rights (Denominator)
following Conversion Notice from Atlas
Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 4
convertible bonds in Oxurion resulting in a EUR 100,000 capital
increase. This is part of Atlas Special Opportunities, LLC’s EUR 20
million Capital Commitment1 that will allow Oxurion to focus on
progressing its novel and differentiated back of the eye drug
candidate targeting potential market opportunities of over USD 5
billion.
Leuven, BELGIUM, Boston, MA, US –
November 6, 2023 – 08.00 PM CET – In accordance with
article 15 of the Belgian Act of May 2, 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or
“Oxurion”), announces the below information, following the issuance
of 155,279,503 new ordinary shares on November 6, 2023, for a total
amount of EUR 100,000, as the result of the conversion of 4
convertible bonds, pursuant to the Capital Commitment entered into
with Atlas Special Opportunities, LLC.
Following completion of the capital increase
through the conversion of the convertible bonds, the total number
of shares issued by Oxurion amounts to 3,112,043,514 outstanding
ordinary shares carrying voting rights (compared to 2,956,764,011
outstanding ordinary shares previously). This number will be used
as the denominator for the calculation of the percentages of
shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
83,106,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
3,112,043,514 |
- Total number of ordinary shares (=
denominator)
|
3,112,043,514 |
- Number of outstanding, granted
rights to subscribe to securities carrying voting rights not yet
issued:
|
|
- 590,500 subscription rights (“SRs”)
issued on November 20, 2017, entitling their holders to subscribe
to a total number of 590,500 securities carrying voting rights (all
ordinary shares);
- 60,000 SRs issued on December 23,
2020, entitling their holders to subscribe to a total number of
60,000 securities carrying voting rights (all ordinary
shares);
- 972,250 SRs issued on April 14,
2021, entitling their holders to subscribe to a total number of
972,250 securities carrying voting rights (all ordinary
shares);
- 532,500 SRs issued on September 22,
2021, entitling their holders to subscribe to a total number of
532,500 securities carrying voting rights (all ordinary
shares);
- 604,405 SRs issued on December 30,
2021, entitling their holders to subscribe to a total number of
604,405 securities carrying voting rights (all ordinary
shares);
- 268 convertible bonds issued on
March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August
10, 2023, September 15, 2023, October 20, 2023, and October 24,
2023, entitling its holder, Atlas Special Opportunities, LLC, to
subscribe to a total number of securities carrying voting rights
(all ordinary shares) in accordance with the terms and conditions
of these convertible bonds pursuant to the Subscription Agreement
entered into between the Company and Atlas Special Opportunities,
LLC on March 1, 2023, as amended on October 3, 2023.
- 100 convertible bonds issued on
December 20, 2021, entitling their holders (Kreos Capital VI (UK)
Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax
Medison Finance (Cayman) L.P.) to subscribe to a total number of
securities carrying voting rights (all ordinary shares) in
accordance with the terms and conditions of these convertible bonds
as attached to the Agreement for the provision of a Loan Facility
entered into between the Company, Kreos Capital VI (UK) Limited,
Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance
(Cayman) L.P., on November 21, 2021 (as amended from time to
time).
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
US Conway Communications Mary T.
Conwaymtconway@conwaycommsir.com |
1 Press release Oxurion, 02/03/2023
Oxurion Nv (LSE:0G99)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Oxurion Nv (LSE:0G99)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024